MXPA00010241A - Composicion farmaceutica que comprende el factor viii y liposomas neutrales.. - Google Patents

Composicion farmaceutica que comprende el factor viii y liposomas neutrales..

Info

Publication number
MXPA00010241A
MXPA00010241A MXPA00010241A MXPA00010241A MXPA00010241A MX PA00010241 A MXPA00010241 A MX PA00010241A MX PA00010241 A MXPA00010241 A MX PA00010241A MX PA00010241 A MXPA00010241 A MX PA00010241A MX PA00010241 A MXPA00010241 A MX PA00010241A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
protein
factor viii
colloidal particles
polypeptide
Prior art date
Application number
MXPA00010241A
Other languages
English (en)
Spanish (es)
Inventor
Israel Nur
Original Assignee
Opperbas Holding Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opperbas Holding Bv filed Critical Opperbas Holding Bv
Publication of MXPA00010241A publication Critical patent/MXPA00010241A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MXPA00010241A 1998-04-27 1999-04-23 Composicion farmaceutica que comprende el factor viii y liposomas neutrales.. MXPA00010241A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL12422498 1998-04-27
PCT/IL1999/000217 WO1999055306A1 (en) 1998-04-27 1999-04-23 Pharmaceutical composition comprising factor viii and neutral liposomes

Publications (1)

Publication Number Publication Date
MXPA00010241A true MXPA00010241A (es) 2004-09-06

Family

ID=11071435

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA00010241A MXPA00010241A (es) 1998-04-27 1999-04-23 Composicion farmaceutica que comprende el factor viii y liposomas neutrales..

Country Status (12)

Country Link
US (2) US6593294B1 (https=)
EP (1) EP1079805B1 (https=)
JP (1) JP4545928B2 (https=)
AT (1) ATE283034T1 (https=)
AU (1) AU747391B2 (https=)
BR (1) BR9909978A (https=)
CA (1) CA2329768C (https=)
DE (1) DE69922189T2 (https=)
ES (1) ES2233036T3 (https=)
MX (1) MXPA00010241A (https=)
PT (1) PT1079805E (https=)
WO (1) WO1999055306A1 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625584B2 (en) * 2000-11-30 2009-12-01 The Research Foundation Of State University Of New York Method of complexing a protein by the use of a dispersed system and proteins thereof
AU2002239607A1 (en) * 2000-11-30 2002-06-11 Baxter Healthcare Corporation Ahf associated dispersion system and method for preparation
US8110218B2 (en) * 2000-11-30 2012-02-07 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein-lipid complexes
DE60335469D1 (de) * 2002-07-02 2011-02-03 Univ Texas Radioaktiv markierte verbindungen und liposome und ihre herstellungs- und anwendungsverfahren
US7351688B2 (en) * 2003-02-05 2008-04-01 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein formulations
CN1774281B (zh) * 2003-04-15 2010-10-13 奥珀百思控股公司 包含蛋白质和/或多肽以及胶体颗粒的药物组合物
WO2005017526A1 (en) 2003-08-05 2005-02-24 The Research Foundation Of State University Of New York Reconstitution medium for protein and peptide formulations
US20070003607A1 (en) * 2003-09-02 2007-01-04 Vibhudutta Awasthi Neutral liposome-encapsulated compounds and methods of making and using thereof
US7208174B2 (en) * 2003-12-18 2007-04-24 Hoffmann-La Roche Inc. Liposome compositions
ATE489942T1 (de) * 2004-01-23 2010-12-15 Camurus Ab Ternäre nichtlamellare lipidzusammensetzungen
PT2363414T (pt) 2004-11-12 2022-08-04 Bayer Healthcare Llc Modificação de fviii direcionada a sítio
CA2605068A1 (en) * 2005-04-15 2006-10-26 The Board Of Regents Of The University Of Texas System Delivery of sirna by neutral lipid compositions
CA2613705A1 (en) * 2005-06-29 2007-01-04 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic pr0tein-lip1d complexes
WO2007021822A2 (en) 2005-08-09 2007-02-22 The Research Foundation Of State Of University Of New York At Buffalo Compositions and methods of preparation of liposomal microparticulate il-12
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
WO2007117469A2 (en) * 2006-03-30 2007-10-18 The Research Foundation Of State University Of New York Compositions of less immunogenic and long-circulating protein-lipid complexes
US7875288B2 (en) * 2006-03-30 2011-01-25 The Research Foundation Of State University Of New York Method for treating blood coagulation disorders
PT2101821E (pt) * 2006-12-15 2014-10-03 Baxter Int Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo
CA2673459C (en) 2006-12-22 2016-09-13 Stefan Schulte Modified coagulation factors with prolonged in vivo half-life
PL2291523T3 (pl) 2008-06-24 2015-05-29 Csl Behring Gmbh Czynnik VIII, czynnik von Willebranda lub ich kompleksy o wydłużonym okresie półtrwania in vivo
EP2299953B1 (en) 2008-07-14 2017-04-12 Polypid Ltd. Sustained-release drug carrier composition
WO2010135714A2 (en) 2009-05-22 2010-11-25 The Methodist Hospital Research Institute Methods for modulating adipocyte expression using microrna compositions
IN2012DN00570A (https=) 2009-07-14 2015-06-12 Polypid Ltd
WO2011025893A1 (en) 2009-08-28 2011-03-03 The Trustees Of Columbia University In The City Of New York Systems, methods, and devices for production of gas-filled microbubbles
WO2011075557A1 (en) 2009-12-16 2011-06-23 The Trustees Of Columbia University In The City Of New York Methods, devices, and systems for on-demand ultrasound-triggered drug delivery
US20130028959A1 (en) 2009-12-16 2013-01-31 Massachusetts Institute Of Technology Liposomes for Preventing the Spread of HIV
EP2525778B1 (en) 2010-01-19 2018-08-01 Polypid Ltd. Sustained-release nucleic acid matrix compositions
US8637448B2 (en) * 2010-09-14 2014-01-28 University Of Rochester Recombinant factor VIII having enhanced stability following mutation at the A1-C2 domain interface
DE102010043733A1 (de) 2010-11-10 2012-05-10 Oxprotect Gmbh Unbeladene PEGylierte Liposomen zur Verwendung als Arzneimittel zur Prophylaxe und Therapie von hämorrhagischen und thrombo- embolischen Erkrankungen
WO2013120939A1 (en) 2012-02-15 2013-08-22 Csl Behring Gmbh Von willebrand factor variants having improved factor viii binding affinity
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
BR112016030950A2 (pt) 2014-07-02 2018-03-27 Csl Ltd polipeptídeo modificado que se liga ao fator viii, complexo, composição farmacêutica, métodos para tratar uma coagulopatia, para produzir um polipeptídeo que compreende um vwf modificado e para aumentar a afinidade de ligação ao fator viii do vwf e a meia-vida do fator viii, uso de um polipeptídeo modificado ou de um complexo, polinucleotídeo, plasmídeo ou vetor, e, célula hospedeira.
GB201417589D0 (en) * 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
ES2772933T3 (es) 2015-03-06 2020-07-08 CSL Behring Lengnau AG Factor de von Willebrand modificado que tiene una semivida mejorada
EP3297656B1 (en) 2015-05-22 2020-01-08 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
JP6651548B2 (ja) 2015-05-22 2020-02-19 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 改変フォン・ヴィルブランド因子を製造するための方法
GB201518171D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
GB201518170D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
GB201518172D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine
RU2018128613A (ru) 2016-01-07 2020-02-07 Цсл Беринг Ленгнау Аг Мутированный фактор фон виллебранда
DK3400002T3 (da) 2016-01-07 2022-04-11 CSL Behring Lengnau AG Muteret, trunkeret von willebrand faktor
WO2017220099A1 (en) 2016-06-24 2017-12-28 Statens Serum Institut Adjuvants with modified drainage properties
WO2018005657A1 (en) 2016-06-28 2018-01-04 Verily Life Sciences Llc Serial filtration to generate small cholesterol-containing liposomes
US11814421B2 (en) 2016-11-11 2023-11-14 CSL Behring Lengnau AG Truncated von Willebrand Factor polypeptides for treating hemophilia
SG11201903954WA (en) 2016-11-11 2019-05-30 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7900459A (nl) 1979-01-19 1980-07-22 Hendrik Coenraad Hemker Prof D Farmaceutisch preparaat en werkwijze ter bereiding daarvan.
JPS56127307A (en) * 1980-03-11 1981-10-06 Green Cross Corp:The Blood-coagulation factor 8 pharmaceutical for oral administration
US4348384A (en) 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
US5527528A (en) * 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
AU7217891A (en) * 1990-02-13 1991-09-03 Oxford Virology Plc Therapeutic agents, and intermediates for the synthesis thereof
US6326353B1 (en) * 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method

Also Published As

Publication number Publication date
ES2233036T3 (es) 2005-06-01
US6593294B1 (en) 2003-07-15
ATE283034T1 (de) 2004-12-15
CA2329768C (en) 2008-06-10
EP1079805B1 (en) 2004-11-24
CA2329768A1 (en) 1999-11-04
JP4545928B2 (ja) 2010-09-15
PT1079805E (pt) 2005-03-31
DE69922189D1 (de) 2004-12-30
US20030134778A1 (en) 2003-07-17
AU3441499A (en) 1999-11-16
WO1999055306A1 (en) 1999-11-04
AU747391B2 (en) 2002-05-16
JP2002512947A (ja) 2002-05-08
DE69922189T2 (de) 2005-11-10
EP1079805A1 (en) 2001-03-07
US6930087B2 (en) 2005-08-16
BR9909978A (pt) 2000-12-26

Similar Documents

Publication Publication Date Title
MXPA00010241A (es) Composicion farmaceutica que comprende el factor viii y liposomas neutrales..
EP0783299A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES
DE69312947D1 (de) Proteinhaftige arzneimittel mit verzögerter wirkstoffabgabe
DK0682524T3 (da) Farmaceutiske præparater indeholdende et baktericid/permeabilitetsforøgende protein og et afspændingsmiddel
EP1093819A3 (en) Compounds and compositions for delivering active agents
AU6819294A (en) Oral drug delivery compositions and methods
FI962154A0 (fi) Koostumus terapeuttisten tuotteiden in vivo valmistusta varten
IL100731A0 (en) Mixed specificity fusion protein and pharmaceutical composition containing it
AU2272097A (en) Drug delivery compositions suitable for intravenous injection
IS2070B (is) Stöðugar interferónlyfjablöndur á vökvaformi
WO1997010851A3 (en) Nucleic acid delivery vehicle
IL145620A0 (en) A polypeptide containing an immunogenic portion of a breast tumor protein and pharmaceutical compositions containing the same
EP1273304A3 (en) Use of interleukin-15
WO2004019872A3 (en) Oral delivery of modified transferrin fusion proteins
AU5956398A (en) Remedies for lymphocytic tumors
EP0422125A4 (en) Platelet blocking peptides
AU2975899A (en) Colonic delivery of protein or peptide compositions
AU7683296A (en) Peptide conjugates derived from thymic hormones, their use as medicament and compositions containing them
WO2002058589A3 (en) Agents and methods for promoting bone growth
WO2001083783A3 (en) In vivo loading of mhc
PT1633440E (pt) Composição farmacêutica que compreende proteínas e/ou polipéptidos e partículas coloidais
WO1994016723A3 (en) Wound healing composition
WO2001066574A3 (en) Cryptococcal mannoproteins or equivalents thereof for use in modulating neutrophil migration
DE69839694D1 (de) Myelin basic protein peptidfragmente, deren pharmazeutische zusammensetzungen und verwendung gegen multiple sklerose
WO2003087329A3 (en) Targeted cytocidal virionoids for antiangiogenesis

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights
PD Change of proprietorship

Owner name: CANTAB BIOPHARMACEUTICALS PATENTS LIMITED.*

PD Change of proprietorship

Owner name: CANTAB BIOPHARMACEUTICALS PATENTS LIMITED.*